| Year |
Citation |
Score |
| 2021 |
Morse MA, Chawla SP, Wong TZ, Bruckner HW, Hall FL, Gordon EM. Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review. Molecular and Clinical Oncology. 15: 186. PMID 34277005 DOI: 10.3892/mco.2021.2348 |
0.321 |
|
| 2019 |
Chawla SP, Bruckner H, Morse MA, Assudani N, Hall FL, Gordon EM. A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Molecular Therapy Oncolytics. 12: 56-67. PMID 30705966 DOI: 10.1016/J.Omto.2018.12.005 |
0.401 |
|
| 2019 |
Gordon EM, Chawla SP, Hall FL. Survival data following phase 1/2 studies using precision tumor-targeted gene delivery to advanced chemotherapy-resistant malignancies. Journal of Global Oncology. 5: 101-101. DOI: 10.1200/Jgo.2019.5.Suppl.101 |
0.343 |
|
| 2019 |
Gordon EM, Szeto C, Ravicz JR, Reddy S, Morse M, Chawla S, Hall F. Abstract 2556: Enhanced expression of human cyclin G1 (CCNG1) gene in metastatic cancer, a novel biomarker in development for CCNG1 inhibitor therapy Cancer Research. 79: 2556-2556. DOI: 10.1158/1538-7445.Am2019-2556 |
0.401 |
|
| 2018 |
Al-Shihabi A, Chawla SP, Hall FL, Gordon EM. Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy. Molecular Therapy - Oncolytics. 11: 122-126. PMID 30581985 DOI: 10.1016/J.Omto.2018.11.002 |
0.307 |
|
| 2018 |
Gordon EM, Ravicz JR, Liu S, Chawla SP, Hall FL. Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists. Molecular and Clinical Oncology. 9: 115-134. PMID 30101008 DOI: 10.3892/Mco.2018.1657 |
0.429 |
|
| 2018 |
Ravicz J, Liu S, Andrali SS, Reddy SK, Sellappan S, Leong B, Chawla SP, Hall FL, Gordon EM. Differential expression of human cyclin G1 (CCNG1) in cancer: A novel biomarker in development for CCNG1 inhibitor therapy. Journal of Clinical Oncology. 36: e24315-e24315. DOI: 10.1200/Jco.2018.36.15_Suppl.E24315 |
0.414 |
|
| 2017 |
Kim S, Federman N, Gordon EM, Hall FL, Chawla SP. Rexin-G(®), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. Molecular and Clinical Oncology. 6: 861-865. PMID 28588778 DOI: 10.3892/Mco.2017.1231 |
0.392 |
|
| 2016 |
Hall FL, Chawla SP, Chawla NS, Gordon EM. Abstract 2203: Targeting monoclonal antibodies to the tumor microenvironment for cancer immunotherapy Cancer Research. 76: 2203-2203. DOI: 10.1158/1538-7445.Am2016-2203 |
0.367 |
|
| 2011 |
Ignacio JG, Bruckner H, Manalo RE, San Juan FS, Baniqued L, Madamba A, Gordon EM, Hall FL. Tumor-targeted cancer vaccination (GeneVieve Protocol): A phase I/II study of intravenous Rexin-G and Reximmune-C for chemotherapy-resistant cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2589. PMID 28022264 DOI: 10.1200/Jco.2011.29.15_Suppl.2589 |
0.395 |
|
| 2010 |
Hall FL, Levy JP, Reed RA, Petchpud WN, Chua VS, Chawla SP, Gordon EM. Pathotropic targeting advances clinical oncology: tumor-targeted localization of therapeutic gene delivery. Oncology Reports. 24: 829-33. PMID 20811660 DOI: 10.3892/Or.2010.829 |
0.389 |
|
| 2010 |
Gordon EM, Hall FL. Noteworthy clinical case studies in cancer gene therapy: tumor-targeted Rexin-G advances as an efficacious anti-cancer agent. International Journal of Oncology. 36: 1341-53. PMID 20428757 DOI: 10.3892/Ijo_00000619 |
0.378 |
|
| 2010 |
Gordon EM, Hall FL. Rexin-G, a targeted genetic medicine for cancer. Expert Opinion On Biological Therapy. 10: 819-32. PMID 20384524 DOI: 10.1517/14712598.2010.481666 |
0.416 |
|
| 2010 |
Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM, Hall FL. Advanced phase I/II studies of targeted gene delivery in vivo: intravenous Rexin-G for gemcitabine-resistant metastatic pancreatic cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 435-41. PMID 19826403 DOI: 10.1038/Mt.2009.228 |
0.342 |
|
| 2010 |
Bruckner H, Chawla SP, Chua CS, Quon DV, Fernandez L, Saralou A, Fisher M, Gordon EM, Hall FL. Phase I and II studies of intravenous Rexin-G as monotherapy for stage IVb gemcitabine-resistant pancreatic cancer. Journal of Clinical Oncology. 28: 4149-4149. DOI: 10.1200/Jco.2010.28.15_Suppl.4149 |
0.367 |
|
| 2010 |
Ignacio JG, Chawla SP, Manalo RE, Baniqued L, Juan FSS, Madamba A, Hall FL, Gordon EM. A phase I/II study of intravenous Rexin-G and Reximmune-C for cancer immunotherapy: The GeneVieve protocol. Journal of Clinical Oncology. 28: 2546-2546. DOI: 10.1200/Jco.2010.28.15_Suppl.2546 |
0.357 |
|
| 2010 |
Ganjoo KN, Chawla SP, Chua VS, Fernandez L, Quon DV, Saralou A, Hall FL, Gordon EM. Advanced phase I/II evaluation of tumor-targeted gene delivery: Intravenous retrovector encoding mutant anticyclin G1 as stand-alone therapy for chemotherapy-resistant bone and soft tissue sarcoma. Journal of Clinical Oncology. 28: 10010-10010. DOI: 10.1200/Jco.2010.28.15_Suppl.10010 |
0.369 |
|
| 2009 |
Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM. Evaluation of the safety and efficacy of pathotropic nanoparticles bearing a dominant negative cyclin G1 construct for chemoresistant osteosarcoma and other sarcomas: Phase I, II, and III studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 10513. PMID 27963649 DOI: 10.1200/Jco.2009.27.15_Suppl.10513 |
0.309 |
|
| 2009 |
Gordon EM, Hall FL. The 'timely' development of Rexin-G: first targeted injectable gene vector (review). International Journal of Oncology. 35: 229-38. PMID 19578735 DOI: 10.3892/Ijo_00000332 |
0.399 |
|
| 2009 |
Chawla SP, Chua VS, Fernandez L, Quon D, Saralou A, Blackwelder WC, Hall FL, Gordon EM. Phase I/II and phase II studies of targeted gene delivery in vivo: intravenous Rexin-G for chemotherapy-resistant sarcoma and osteosarcoma. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1651-7. PMID 19532136 DOI: 10.1038/Mt.2009.126 |
0.334 |
|
| 2008 |
Chawla SP, Chua VS, Mohan V, Alzwahereh K, Kalra A, Quon D, Gordon EM, Hall FL. Phase I/II study of targeted gene delivery in vivo-intravenous infusions of Rexin-G-demonstrate significant biologic activity by FDG PET-CT without toxicity in patients with progressive chemo-resistant sarcoma, breast cancer and pancreatic cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 14509. PMID 27950784 DOI: 10.1200/Jco.2008.26.15_Suppl.14509 |
0.405 |
|
| 2008 |
Cornelio GH, Lorenzo CC, Lopez FF, Hall FL, Gordon EM. Phase I study of sequential targeted gene delivery: Intravenous infusions of Rexin-G followed by Reximmune-C induce tumor necrosis and recruitment of tumor infiltrating lymphocytes in cancerous lesions. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3077. PMID 27947690 DOI: 10.1200/Jco.2008.26.15_Suppl.3077 |
0.41 |
|
| 2008 |
Gordon EM, Levy JP, Reed RA, Petchpud WN, Liu L, Wendler CB, Hall FL. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ. International Journal of Oncology. 33: 665-75. PMID 18813779 DOI: 10.3892/Ijo_00000052 |
0.422 |
|
| 2007 |
Gordon EM, Chan MT, Geraldino N, Lopez FF, Cornelio GH, Lorenzo CC, Levy JP, Reed RA, Liu L, Hall FL. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes. International Journal of Oncology. 30: 1297-307. PMID 17487349 DOI: 10.3892/Ijo.30.6.1297 |
0.399 |
|
| 2006 |
Gordon EM, Lopez FF, Cornelio GH, Lorenzo CC, Levy JP, Reed RA, Liu L, Bruckner HW, Hall FL. Pathotropic nanoparticles for cancer gene therapy Rexin-G IV: three-year clinical experience. International Journal of Oncology. 29: 1053-64. PMID 17016635 DOI: 10.3892/Ijo.29.5.1053 |
0.427 |
|
| 2005 |
Gordon EM, Hall FL. Nanotechnology blooms, at last (Review). Oncology Reports. 13: 1003-7. PMID 15870914 DOI: 10.3892/Or.13.6.1003 |
0.35 |
|
| 2004 |
Dong D, Dubeau L, Bading J, Nguyen K, Luna M, Yu H, Gazit-Bornstein G, Gordon EM, Gomer C, Hall FL, Gambhir SS, Lee AS. Spontaneous and controllable activation of suicide gene expression driven by the stress-inducible grp78 promoter resulting in eradication of sizable human tumors. Human Gene Therapy. 15: 553-61. PMID 15212714 DOI: 10.1089/104303404323142006 |
0.379 |
|
| 2004 |
Guibinga GH, Hall FL, Gordon EM, Ruoslahti E, Friedmann T. Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype. Molecular Therapy : the Journal of the American Society of Gene Therapy. 9: 76-84. PMID 14741780 DOI: 10.1016/J.Ymthe.2003.09.018 |
0.355 |
|
| 2004 |
Gordon EM, Cornelio GH, Lorenzo CC, Levy JP, Reed RA, Liu L, Hall FL. First clinical experience using a 'pathotropic' injectable retroviral vector (Rexin-G) as intervention for stage IV pancreatic cancer. International Journal of Oncology. 24: 177-85. PMID 14654955 DOI: 10.3892/Ijo.24.1.177 |
0.391 |
|
| 2004 |
Gordon E, Pahre J, Fuchs M, Levy J, Hall F. Molecular Engineering of “Pathotropic” Targeting for Cancer Gene Therapy Bioprocessing Journal. 3: 21-26. DOI: 10.12665/J31.Gordon |
0.343 |
|
| 2002 |
Lenz HJ, Anderson WF, Hall FL, Gordon EM. Clinical protocol. Tumor site specific phase I evaluation of safety and efficacy of hepatic arterial infusion of a matrix-targeted retroviral vector bearing a dominant negative cyclin G1 construct as intervention for colorectal carcinoma metastatic to liver. Human Gene Therapy. 13: 1515-37. PMID 12215272 DOI: 10.1089/10430340260185148 |
0.314 |
|
| 2001 |
Andrades JA, Santamaría JA, Wu LT, Hall FL, Nimni ME, Becerra J. Production of a recombinant human basic fibroblast growth factor with a collagen binding domain Protoplasma. 218: 95-103. PMID 11732325 DOI: 10.1007/Bf01288365 |
0.349 |
|
| 2001 |
Masood R, Gordon EM, Whitley MD, Wu BW, Cannon P, Evans L, Anderson WF, Gill P, Hall FL. Retroviral vectors bearing IgG-binding motifs for antibody-mediated targeting of vascular endothelial growth factor receptors. International Journal of Molecular Medicine. 8: 335-43. PMID 11562769 DOI: 10.3892/Ijmm.8.4.335 |
0.368 |
|
| 2001 |
Andrades JA, Wu LT, Hall FL, Nimni ME, Becerra J. Engineering, expression, and renaturation of a collagen-targeted human bFGF fusion protein. Growth Factors Journal. 18: 261-275. PMID 11519825 DOI: 10.3109/08977190109029115 |
0.35 |
|
| 2001 |
Gordon EM, Zhu NL, Forney Prescott M, Chen ZH, Anderson WF, Hall FL. Lesion-targeted injectable vectors for vascular restenosis. Human Gene Therapy. 12: 1277-87. PMID 11440621 DOI: 10.1089/104303401750270931 |
0.317 |
|
| 2001 |
Xu F, Prescott MF, Liu PX, Chen ZH, Liau G, Gordon EM, Hall FL. Long term inhibition of neointima formation in balloon-injured rat arteries by intraluminal instillation of a matrix-targeted retroviral vector bearing a cytocidal mutant cyclin G1 construct. International Journal of Molecular Medicine. 8: 19-30. PMID 11408944 DOI: 10.3892/Ijmm.8.1.19 |
0.367 |
|
| 2001 |
Gordon EM, Chen ZH, Liu L, Whitley M, Liu L, Wei D, Groshen S, Hinton DR, Anderson WF, Beart RW, Hall FL. Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Human Gene Therapy. 12: 193-204. PMID 11177556 DOI: 10.1089/104303401750061258 |
0.398 |
|
| 2000 |
Hall FL, Kaiser A, Liu L, Chen ZH, Hu J, Nimni ME, Beart RW, Gordon EM. Design, expression, and renaturation of a lesion-targeted recombinant epidermal growth factor-von Willebrand factor fusion protein: efficacy in an animal model of experimental colitis. International Journal of Molecular Medicine. 6: 635-43. PMID 11078822 DOI: 10.3892/Ijmm.6.6.635 |
0.377 |
|
| 2000 |
Wang Y, Xu F, Hall FL. The MAT1 cyclin-dependent kinase-activating kinase (CAK) assembly/targeting factor interacts physically with the MCM7 DNA licensing factor. Febs Letters. 484: 17-21. PMID 11056214 DOI: 10.1016/S0014-5793(00)02117-7 |
0.348 |
|
| 2000 |
Hall FL, Liu L, Zhu NL, Stapfer M, Anderson WF, Beart RW, Gordon EM. Molecular engineering of matrix-targeted retroviral vectors incorporating a surveillance function inherent in von Willebrand factor. Human Gene Therapy. 11: 983-93. PMID 10811227 DOI: 10.1089/10430340050015293 |
0.357 |
|
| 2000 |
Liu L, Anderson WF, Beart RW, Gordon EM, Hall FL. Incorporation of tumor vasculature targeting motifs into moloney murine leukemia virus env escort proteins enhances retrovirus binding and transduction of human endothelial cells. Journal of Virology. 74: 5320-8. PMID 10799609 DOI: 10.1128/Jvi.74.11.5320-5328.2000 |
0.386 |
|
| 2000 |
Kampmeier J, Behrens A, Wang Y, Yee A, Anderson WF, Hall FL, Gordon EM, McDonnell PJ. Inhibition of rabbit keratocyte and human fetal lens epithelial cell proliferation by retrovirus-mediated transfer of antisense cyclin G1 and antisense MAT1 constructs. Human Gene Therapy. 11: 1-8. PMID 10646634 DOI: 10.1089/10430340050016102 |
0.406 |
|
| 2000 |
Xu F, Wang Y, Hall FL. Molecular cloning and characterization of FX3, a novel zinc-finger protein. Oncology Reports. 7: 995-1996. DOI: 10.3892/Or.7.5.995 |
0.383 |
|
| 2000 |
Wu KJ, Yee A, Zhu NL, Gordon EM, Hall FL. Characterization of differential gene expression in monkey arterial neointima following balloon catheter injury. International Journal of Molecular Medicine. 6: 433-473. DOI: 10.3892/Ijmm.6.4.433 |
0.334 |
|
| 2000 |
Behrens A, Kampmeier J, Liu PX, Li L, Wang Y, Yee A, Anderson WF, Hall FL, Gordon EM, McDonnell PJ. Inhibition Of Rabbit Keratocyte Cell Proliferation By Retrovirus-Mediated Transfer Of Antisense Cyclin G1 And Antisense Mat1 Constructs To Prevent Corneal Haze Development After Photorefractive/Phototherapeutic Keratectomy. Cornea. 19. DOI: 10.1097/00003226-200011002-00016 |
0.349 |
|
| 1999 |
Andrades JA, Han B, Becerra J, Sorgente N, Hall FL, Nimni ME. A Recombinant Human TGF-β1 Fusion Protein with Collagen-Binding Domain Promotes Migration, Growth, and Differentiation of Bone Marrow Mesenchymal Cells Experimental Cell Research. 250: 485-498. PMID 10413602 DOI: 10.1006/Excr.1999.4528 |
0.316 |
|
| 1998 |
Wang MB, Billings KR, Venkatesan N, Hall FL, Srivatsan ES. Inhibition Of Cell Proliferation In Head And Neck Squamous Cell Carcinoma Cell Lines With Antisense Cyclin D1 Otolaryngology-Head and Neck Surgery. 119: 593-599. PMID 9852531 DOI: 10.1016/S0194-5998(98)70017-8 |
0.365 |
|
| 1998 |
Weimin Wu B, Cannon PM, Gordon EM, Hall FL, Anderson WF. Characterization of the proline-rich region of murine leukemia virus envelope protein. Journal of Virology. 72: 5383-91. PMID 9620992 DOI: 10.1128/Jvi.72.7.5383-5391.1998 |
0.308 |
|
| 1997 |
Hall FL, Gordon EM, Wu L, Zhu NL, Skotzko MJ, Starnes VA, Anderson WF. Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Human Gene Therapy. 8: 2183-92. PMID 9449372 DOI: 10.1089/Hum.1997.8.18-2183 |
0.373 |
|
| 1997 |
Driscoll B, Wu L, Buckley S, Hall FL, Anderson KD, Warburton D. Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth American Journal of Physiology - Lung Cellular and Molecular Physiology. 273: L941-L949. PMID 9374720 DOI: 10.1152/Ajplung.1997.273.5.L941 |
0.372 |
|
| 1997 |
Han B, Hall FL, Nimni ME. Refolding of a Recombinant Collagen-Targeted TGF-β2 Fusion Protein Expressed inEscherichia coli Protein Expression and Purification. 11: 169-178. PMID 9367813 DOI: 10.1006/Prep.1997.0784 |
0.336 |
|
| 1997 |
Chen DS, Zhu NL, Hung G, Skotzko MJ, Hinton DR, Tolo V, Hall FL, Anderson WF, Gordon EM. Retroviral vector-mediated transfer of an antisense cyclin G1 construct inhibits osteosarcoma tumor growth in nude mice. Human Gene Therapy. 8: 1667-74. PMID 9322869 DOI: 10.1089/Hum.1997.8.14-1667 |
0.397 |
|
| 1997 |
Gordon EM, Skotzko M, Kundu RK, Han B, Andrades J, Nimni M, Anderson WF, Hall FL. Capture and expansion of bone marrow-derived mesenchymal progenitor cells with a transforming growth factor-beta1-von Willebrand's factor fusion protein for retrovirus-mediated delivery of coagulation factor IX. Human Gene Therapy. 8: 1385-94. PMID 9295133 DOI: 10.1089/Hum.1997.8.11-1385 |
0.303 |
|
| 1997 |
Zhu NL, Wu L, Liu PX, Gordon EM, Anderson WF, Starnes VA, Hall FL. Downregulation of cyclin G1 expression by retrovirus-mediated antisense gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation. Circulation. 96: 628-35. PMID 9244236 DOI: 10.1161/01.Cir.96.2.628 |
0.373 |
|
| 1996 |
Tuan TL, Cheung DT, Wu LT, Yee A, Gabriel S, Han B, Morton L, Nimni ME, Hall FL. Engineering, expression and renaturation of targeted TGF-beta fusion proteins. Connective Tissue Research. 34: 1-9. PMID 8835843 DOI: 10.3109/03008209609028888 |
0.354 |
|
| 1996 |
Gordon EM, Venkatesan N, Salazar R, Tang H, Schmeidler-Sapiro K, Buckley S, Warburton D, Hall FL. Factor XII-induced mitogenesis is mediated via a distinct signal transduction pathway that activates a mitogen-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America. 93: 2174-9. PMID 8700904 DOI: 10.1073/Pnas.93.5.2174 |
0.33 |
|
| 1996 |
Yee A, Wu L, Liu L, Kobayashi R, Xiong Y, Hall FL. Biochemical Characterization of the Human Cyclin-dependent Protein Kinase Activating Kinase IDENTIFICATION OF p35 AS A NOVEL REGULATORY SUBUNIT Journal of Biological Chemistry. 271: 471-477. PMID 8550604 DOI: 10.1074/Jbc.271.1.471 |
0.357 |
|
| 1995 |
Zeichner-David M, Hall F, Williams R, Thiemann F, Yen S, MacDougall M, Slavkin HC. Characterization of protein kinases involved in dentinogenesis. Connective Tissue Research. 33: 87-95. PMID 7554967 DOI: 10.3109/03008209509016987 |
0.32 |
|
| 1994 |
Dohadwala M, da Cruz e Silva EF, Hall FL, Williams RT, Carbonaro-Hall DA, Nairn AC, Greengard P, Berndt N. Phosphorylation and inactivation of protein phosphatase 1 by cyclin-dependent kinases. Proceedings of the National Academy of Sciences of the United States of America. 91: 6408-12. PMID 8022797 DOI: 10.1073/Pnas.91.14.6408 |
0.336 |
|
| 1994 |
Williams RT, Wu L, Carbonaro-Hall DA, Hall FL. Identification, assay, and purification of a Cdc2-activating threonine-161 protein kinase from human cells. Archives of Biochemistry and Biophysics. 314: 99-106. PMID 7944411 DOI: 10.1006/Abbi.1994.1416 |
0.359 |
|
| 1993 |
Bui KC, Wu F, Buckley S, Wu L, Williams R, Carbonaro-Hall D, Hall FL, Warburton D. Cyclin A expression in normal and transformed alveolar epithelial cells. American Journal of Respiratory Cell and Molecular Biology. 9: 115-25. PMID 8338681 DOI: 10.1165/Ajrcmb/9.2.115 |
0.345 |
|
| 1993 |
Albers MW, Brown EJ, Tanaka A, Williams RT, Hall FL, Schreiber SL. An FKBP-rapamycin-sensitive, cyclin-dependent kinase activity that correlates with the FKBP-rapamycin-induced G1 arrest point in MG-63 cells. Annals of the New York Academy of Sciences. 696: 54-62. PMID 8109857 DOI: 10.1111/J.1749-6632.1993.Tb17142.X |
0.339 |
|
| 1992 |
Elledge SJ, Richman R, Hall FL, Williams RT, Lodgson N, Harper JW. CDK2 encodes a 33-kDa cyclin A-associated protein kinase and is expressed before CDC2 in the cell cycle. Proceedings of the National Academy of Sciences of the United States of America. 89: 2907-11. PMID 1372993 DOI: 10.1073/Pnas.89.7.2907 |
0.368 |
|
| 1992 |
Sanghera JS, Hall FL, Warburton D, Campbell D, Pelech SL. Identification of epidermal growth factor Thr-669 phosphorylation site peptide kinases as distinct MAP kinases and p34cdc2 Bba - Molecular Cell Research. 1135: 335-342. PMID 1320411 DOI: 10.1016/0167-4889(92)90240-C |
0.305 |
|
| 1991 |
Hall FL, Vulliet PR. Proline-directed protein phosphorylation and cell cycle regulation. Current Opinion in Cell Biology. 3: 176-84. PMID 1831990 DOI: 10.1016/0955-0674(91)90136-M |
0.369 |
|
| 1991 |
Braun RK, Vulliet PR, Carbonaro-Hall DA, Hall FL. Phosphorylation of RII subunit and attenuation of cAMP-dependent protein kinase activity by proline-directed protein kinase. Archives of Biochemistry and Biophysics. 289: 187-91. PMID 1654846 DOI: 10.1016/0003-9861(91)90460-Z |
0.333 |
|
| Show low-probability matches. |